Compare FIBK & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FIBK | TMDX |
|---|---|---|
| Founded | 1879 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.8B |
| IPO Year | 1997 | 2019 |
| Metric | FIBK | TMDX |
|---|---|---|
| Price | $35.61 | $99.58 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 9 |
| Target Price | $35.63 | ★ $148.22 |
| AVG Volume (30 Days) | ★ 1.2M | 807.3K |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 5.46% | N/A |
| EPS Growth | 34.25 | ★ 382.18 |
| EPS | 2.94 | ★ 4.87 |
| Revenue | N/A | ★ $605,494,000.00 |
| Revenue This Year | N/A | $24.25 |
| Revenue Next Year | $4.91 | $18.75 |
| P/E Ratio | ★ $12.07 | $20.58 |
| Revenue Growth | N/A | ★ 37.13 |
| 52 Week Low | $25.81 | $89.65 |
| 52 Week High | $39.26 | $156.00 |
| Indicator | FIBK | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 59.16 | 38.23 |
| Support Level | $31.37 | $93.08 |
| Resistance Level | $36.35 | $120.60 |
| Average True Range (ATR) | 0.74 | 5.24 |
| MACD | 0.15 | -0.83 |
| Stochastic Oscillator | 83.70 | 12.82 |
First Interstate BancSystem Inc is a financial holding company. It is the parent company of First Interstate Bank, a community bank offering a range of internet, mobile, and other banking and financial services throughout Idaho, Montana, Oregon, South Dakota, Washington, and Wyoming. It delivers a range of financial products and services to both retail and commercial customers in industries like agriculture, construction, education, energy, governmental services, healthcare, mining, professional services, retail, tourism and wholesale trade. It generates majority of income from interest charged on loans, and interest and dividends earned on investments.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.